Drug intelligence / Profile preview

placebo + tecemotide

Development stage: Unknown
Lead developer: Merck KGaA
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

This is a combination of placebo and tecemotide, used as a control or comparator arm in clinical trials evaluating the efficacy and safety of tecemotide. Tecemotide is a synthetic lipopeptide antigen used in investigational therapeutic cancer vaccines designed to induce an immune response against MUC1, a glycoprotein antigen overexpressed on various cancers such as lung, breast, prostate, and colorectal cancer. The vaccine aims to stimulate cellular immunity leading to tumor rejection. Placebo serves as an inactive substance for comparison purposes in clinical studies[2][3][8].

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on placebo + tecemotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo + tecemotide.

Explore the full profile